SUNPHARMA
Sun Pharmaceutical Industries
Sun Pharmaceutical Industries (SUNPHARMA) Stock Analysis & Case Study
Is SUNPHARMA a good buy? The data-driven verdict.
Sun Pharmaceutical Industries (SUNPHARMA) trades at ₹1,863,on the numbers it mixed signals, a Downstox Snapshot Score of 51/100.
On the numbers, Sun Pharmaceutical Industries (SUNPHARMA) mixed signals, a Downstox Snapshot Score of 51/100, weighing premium at 35.8× earnings, ROE of 16.0%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
The Downstox take on SUNPHARMA
The tension here is a 35.8 P/E sitting on returns that are merely good, not exceptional: 16% ROE and 20.5% ROCE describe a well-run business, but not one usually worth paying nearly 36 times earnings for. So the multiple is buying a future the current returns do not yet justify, likely a bet on the specialty pipeline maturing into higher margins. The thin 0.86% yield says cash is being kept inside, and a Piotroski score of 4 is the soft spot to watch: confirm the operating momentum that price already assumes.
Downstox editorial view, written by our own analysts. Information, not investment advice.
SUNPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is SUNPHARMA overvalued? SUNPHARMA P/E vs its Pharma
SUNPHARMA's P/E of 35.8× sits above the Pharma peer median of 30.0×, so on earnings it screens richer than peers, while its 0.86% dividend yield is above the peer median of 0.51%.
The bull case for SUNPHARMA
- A healthy 16.0% return on equity.
- Strong ROCE (20.5%) shows the core business earns well above its cost of capital.
The bear case & risks
- At 35.8× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
SUNPHARMA Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. SUNPHARMA scores 4/9,mixed financial health.
SUNPHARMA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy SUNPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 26.5% | 3.8× |
| Zerodha | 22.6% | 4.4× |
| DhanCHEAPEST | 22.0% | 4.5× |
Compare every broker on the SUNPHARMA MTF page.
SUNPHARMA vs peers,Pharma comparison
About Sun Pharmaceutical Industries: sector, index & market-cap context
Sun Pharmaceutical Industries (SUNPHARMA) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 50 index group, with a market capitalisation of ₹4.47L Cr. See more Nifty 50 stocks.
How the SUNPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Sun Pharmaceutical Industries's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SUNPHARMA analysis, FAQs
Is Sun Pharmaceutical Industries (SUNPHARMA) a good buy?
On the numbers, Sun Pharmaceutical Industries (SUNPHARMA) mixed signals, a Downstox Snapshot Score of 51/100, weighing premium at 35.8× earnings, ROE of 16.0%. This is a data snapshot for research, not investment advice.
Is SUNPHARMA overvalued or undervalued?
SUNPHARMA trades at 35.8× earnings versus a peer median of 30.0×, so it screens richer than its Pharma peers.
What is the bull case for SUNPHARMA?
A healthy 16.0% return on equity. Strong ROCE (20.5%) shows the core business earns well above its cost of capital.
What are the risks in SUNPHARMA?
At 35.8× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.